Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03689855 · ClinicalTrials.gov registry record · Phase 2
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC
A Phase 2 study, sponsored by Washington University School of Medicine.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03689855 is a Phase 2 study that has completed, run by Washington University School of Medicine. The registered enrollment target is 21 participants.
The verdict
NCT03689855, a Phase 2 study, has completed, sponsored by Washington University School of Medicine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and atezolizumab in patients with advanced-stage NSCLC patients previously treated with ICB.
Interventions
- DRUG Atezolizumab
- PROCEDURE Biopsy
- DRUG Ramucirumab
- PROCEDURE Peripheral blood draw
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2019-06-05 |
| Est. Completion | 2024-04-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03689855
The ClinicalTrials.gov registry entry for NCT03689855 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Atezolizumab is the first listed.
NCT03689855 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03689855 about?
NCT03689855 is a clinical study titled "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC". Data suggests that combining ramucirumab with immunotherapy in non-small cell lung cancer (NSCLC) patients who have previously received immune checkpoint blockers (ICBs) may be more effective than traditional therapy. The investigators propose a pilot study to test the combination of ramucirumab and...
What is the current status of trial NCT03689855?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2019-06-05. Estimated completion is 2024-04-22.
What interventions are being tested in trial NCT03689855?
The interventions under investigation include: Atezolizumab (DRUG), Biopsy (PROCEDURE), Ramucirumab (DRUG), Peripheral blood draw (PROCEDURE).
Who is sponsoring clinical trial NCT03689855?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.